top of page

Off-the-shelf allogeneic cell therapy to fight cancer

Our solution
ABOUT SAKURA BIO

Our company

Sakura Bio is a start-up company developing an off-the-shelf, allogeneic T-cell therapy to fight cancer.

Our lead product, Skill-T (Super Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. 

The technology was established by Professor Amnon Peled and Dr. Inbal Mishalian at Hadassah Medical Center, and involves a simple, cost effective, proprietary manufacturing process.
 
In contrast to other T-cell based products, such as CAR-T, Skill-T cells have High safety profile, with no Graft-versus-host disease (GVHD), and can be developed as an off-the-shelf T cell product.

 

Comprehensive preclinical studies validated the killing superiority of Skill-T vs. CIK and other T-cell-based therapies in different tumor models. 

 

Skill-T outstanding killing properties of leukemic cells lead Sakura to choose Acute Myeloid Leukemia (AML) as its first-in-man indication for Skill therapy.
Our lead product, Skill therapy (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. 
Sakura bio team
T cell therapy
OUR TEAM

Our team

Leukemia
ADVISORY BOARD

Board of directors

Allogeneic therapy
our science
Sakura Bio science

our science

Sakura Bio
The technology
Sakura Bio TECHNOLOGY
Sakura bio technology

* Skill-T: Super Killer T cells

The technology

Cell therapy
THE NEED
background3.jpg

AML

Acute myeloid leukemia (AML) is a cancer of the blood cells derived from the uncontrolled proliferation and maturation of myeloid progenitor cells.
 
The American Cancer Society estimates that in the United States in 2022 there will be about 20,000 new cases of AML and about 11,500 deaths, almost all in adults.​
 
AML is a life-threatening haematological malignancy; the 5-year survival of patients is disappointingly low, ~ 30%.
 
The first-line treatment of AML is usually chemotherapy, sometimes along with a targeted therapy drug. This might be followed by a stem cell transplant derived from a healthy donor. 
 
However, 50% of all patients who achieved remission of the disease after initial treatment relapse, due to minimal residual disease (MRD). MRD refers to a small number of cancer cells left in the body after treatment that have the potential to cause relapse of the disease.
About 25% of the relapsing patients (mainly elder patients) cannot undergo additional chemotherapy treatment or stem cell transplant due to their physiological conditions.
Currently, there is no available safe second-line treatment for those patients.

 
Sakura bio’s Skill-T based therapy can provide a safe and effective solution for MRD-positive AML patients which are transplantation ineligible.

Sakura Bio AML
Blood Test
PUBLICATION
our science.jpg

Publication

2023 June

Immuno-Oncology summit Europe,

London 2023.

Conference Programs |CHI's Immuno-Oncology Summit Europe | 20-22 June in London 

T cell therapy
CONTACT US

Contact Us

High-Tech Village Givat Ram Campus

Jerusalem, Israel

diklab@sakurabio.com

  • LinkedIn

Thanks for submitting!

bottom of page